Waters Corporation

Waters Corporation

WATNYSE / NASDAQHealthcareLarge cap

$440.45-$16.03 (-3.5%)

Last close · Data as of Nov 20, 2026

Market cap
$37.0B
P/E
57.5x
EV / EBITDA
36.7x
Revenue
$3.2B
Net margin
20.3%
ROCE
20.9%

+16.3% over the last year

Waters Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-0.5%
3M
+8.8%
6M
+29.0%
1Y
+16.3%
5Y
+25.9%

52-week range

Day change -$16.03 (-3.5%) from $456 to $440 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in WAT, bought on each weekday since 2021.

News & filings

What Waters filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity of 25.1% against a peer median of 20.1%.

Concerns (1)

  • The P/E of 57.5 is 111% above the peer median of 27.3.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products.

Read moreShow less

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Sector
Healthcare
Shares outstanding
59.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$37.0B
P/E
57.5x
P/B
14.4x
EV / EBITDA
36.7x
EV / Sales
12.0x
P/S
11.7x
52-week high
$480.07
52-week low
$283.32

Profitability

Operating margin
25.4%
Net margin
20.3%
EBITDA margin
32.6%
ROE
25.1%
ROCE
20.9%
ROA
12.7%
Asset turnover
0.62

Growth

Revenue
$3.2B
Revenue growth, 1Y
7.0%
Revenue CAGR, 3Y
2.1%
Net profit growth, 1Y
0.8%
Free cash flow
$539.8M

Solvency

Current ratio
1.73
Debt / Equity
0.58
Debt / Assets
0.29
CFO / Net profit
1.02
Cash / Market cap
1.6%

Where the revenue went

Of every $100 of FY2025 revenue, $20 was left as net income.

Waters Corporation income statement flow, FY2025
Waters Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$1.3B
RevenueGross profit$1.9B
Gross profitResearch and development$195.7M
Gross profitSelling, general and administrative$830.4M
Gross profitOther operating expenses$47.8M
Gross profitOperating income$802.6M
Operating incomePretax income$754.9M
Operating incomeInterest and other expense$47.7M
Pretax incomeTax and other$112.3M
Pretax incomeNet income$642.6M

Revenue and net profit

Revenue grew 7.0% in FY2025; net profit is the dashed line.

Waters Corporation revenue and net profit by fiscal year
Waters Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$3.0B$707.8M
FY2023$3.0B$642.2M
FY2024$3.0B$637.8M
FY2025$3.2B$642.6M

Cash flows

FY2025: $652.6M from operations, $539.8M free after investment (dashed).

Waters Corporation operating and free cash flow by fiscal year
Waters Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$611.7M$428.2M
FY2023$602.8M$442.2M
FY2024$762.1M$619.6M
FY2025$652.6M$539.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$3.2B+7.0%1Y
EBITDA
$1.0B-0.6%1Y
Net profit
$642.6M+0.8%1Y
Cash from operations
$652.6M-14.4%1Y
Free cash flow
$539.8M-12.9%1Y
Revenue CAGR, 3Y
2.1%
Net profit CAGR, 3Y
-3.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$3.2B$1.0B$642.6M$539.8M25.1%+7.0%+0.8%

Monthly returns

Month-by-month returns of WAT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$5.1B
Liabilities$2.5B
Equity$2.6B
Paid-in capital$2.4B
Retained earnings$10.4B
Treasury stock$10.2B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; WAT highlighted.

P/E against peers

WAT trades at 57.5x earnings against a peer median of 27.3x (a 111% premium).

Not shown (no positive earnings and no EV / Sales): Centene Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Waters CorporationWATthis companyP/E ↑ premium$37.0B57.5x14.4x25.1%36.7x
IDEXX Laboratories, Inc.IDXX$44.5B42.0x27.7x66.0%30.1x
Humana Inc.HUM$42.0B35.4x2.4x6.7%—
Becton, Dickinson and CompanyBDX$41.2B24.6x1.6x6.6%12.1x
Alnylam Pharmaceuticals, Inc.ALNY$40.5B129.2x51.4x39.8%61.6x
Agilent Technologies, Inc.A$39.1B30.0x5.8x19.3%22.1x
Zoetis Inc.ZTS$33.3B12.5x10.0x80.2%9.9x
IQVIA Holdings Inc.IQV$31.2B22.9x4.8x20.9%13.0x
Centene CorporationCNC$31.0B-4.6x1.6x-33.4%-6.5x
Peer median—27.3x5.3x20.1%13.0x

Year-to-date ROI

WAT since 1 January, against earlier years.

Historical volatility

WAT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Waters Corporation operating margin by fiscal year
Waters Corporation operating margin by fiscal year
DateOperating margin
FY202229.7%
FY202327.7%
FY202428.3%
FY202525.4%
LineFY2025
Cost of revenueCost Of Revenue$1.3B
Gross profitGross Profit$1.9B
Operating expensesOperating Expense$1.1B
Research and developmentResearch And Development$195.7M
Selling, general and administrativeSelling General And Administration$830.4M
Depreciation and amortisationDepreciation And Amortization In Income Statement$47.8M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$47.8M
Amortization$47.8M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$47.8M
Total expensesTotal Expenses$2.4B
Pretax incomePretax Income$754.9M

Learn while you research

Academy chapters picked for Waters Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 57.5, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →